Features | Partner Sites | Information | LinkXpress
Sign In
AMPRONIX
TERARECON, INC.
SCHILLER AG

CT Texture Tumor Analysis May Become Useful Biomarker for Localized Esophageal Cancer

By Medimaging International staff writers
Posted on 20 Feb 2013
Computed tomography (CT) texture analysis of primary tumors may become a helpful imaging biomarker in localized esophageal cancer after administering neoadjuvant chemotherapy, according to recent research.

The study’s findings were presented February 9, 2013, at the 2013 Cancer Imaging and Radiation Therapy Symposium, held in Orlando (FL, USA). This symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North American (RSNA).

This study assessed the tumoral texture analysis on baseline and post-treatment CT scans of 31 patients with localized resectable esophageal cancer, with a median age of 63, and who received neoadjuvant chemotherapy between 2007 and 2010. CT scans were performed before and after the use of chemotherapy and before surgery. All patients received fluorouracil-based and platinum chemotherapy followed by surgery. Texture parameters (mean-gray level intensity [MGI], entropy, uniformity, skewness, kurtosis, and standard deviation of histogram [SDH]) were derived for four filter values to highlight structures of different spatial width: 1.0 (fine texture), 1.5–2.0 (medium), and 2.5 (coarse). Median follow-up was 21.9 months. Primary tumors became more homogenous following chemotherapy because entropy decreased and uniformity increased. Smaller change in skewness following chemotherapy was a key prognostic factor—median overall survival was 36.1 months vs. 11.1 months. Lower baseline entropy and lower post-treatment MGI were also tied with increased survival, although they demonstrated only a trend toward significance.

Texture analysis of the CT scans is a post-processing step, which was performed using exclusive software (TexRAD) that enriches the images in ultrafine clarity not visible to the human eye. Specific tumoral characteristics changed consistently following chemotherapy, and some features were linked with overall survival.

“Though these results are for a very small number of patients, they suggest that the tumoral texture features may provide valuable information that could help us to distinguish which patients will do well following chemotherapy and which ones will do poorly,” concluded Connie Yip, MD, the lead study author, a clinical research fellow at King’s College London (UK), and an associate consultant in radiation oncology at the National Cancer Center, Singapore. “As a biomarker for treatment efficacy, this technique could save patients from unnecessary surgery and provide more definitive guidance in developing patient treatment plans with improved outcomes.”

Related Links:

King’s College London




RTI ELECTRONICS AB
RADCAL
SuperSonic Imagine

Channels

MRI

view channel
Image: The Accent MRI pacemaker and Tendril MRI lead (Photo courtesy of St. Jude Medical).

US Patent Allows Full-Body MRI Technology for Use with Pacemakers

A California hospital is first in the United States to conduct magnetic resonance imaging (MRI) of a patient implanted with a new MRI-compatible pacemaker. Cardiothoracic surgeon Raymond Schaerf, MD... Read more

Ultrasound

view channel
Image: Very high magnification micrograph of fibrolamellar hepatocellular carcinoma showing the characteristic laminated fibrosis between the tumor cells with a low N/C ratio. H&E stain (Photo courtesy of Wikimedia Commons).

Hepatocellular Carcinoma Screening Linked with Curative Treatment and Longer Survival in Cirrhosis Patients

Investigators discovered that patients with cirrhosis who underwent surveillance (using liver ultrasound with or without measurement of serum alpha fetoprotein) for hepatocellular carcinoma (HCC) had cancers... Read more

Nuclear medicine

view channel
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).

Early PET-Negative Stage I/II Hodgkin Lymphoma Patients Show Increased Risk of Early Relapse when Radiotherapy Is Not Used

Analysis of a new study indicates an increased risk of early relapse when excluding radiotherapy in early positron emission tomography (PET) scan-negative patients with stage I/II Hodgkin’s lymphoma.... Read more

General/Advanced Imaging

view channel

Secondary Light Emission Generated by Plasmonic Nanostructures May Improve Medical Imaging Technology

New clues into light emission at different wavelengths generated by elements known plasmonic nanostructures may help to improve medical imaging technology. A plasmon is a quantum of plasma oscillation. The plasmon is a quasiparticle resulting from the quantization of plasma oscillations just as photons, and phonons are... Read more

Imaging IT

view channel

Enterprise Image-Viewing System Receives FDA Clearance for Mobile Diagnosis on All Modalities

An enterprise image-viewing system is now cleared in the United States for diagnosis on mobile devices, for all imaging modalities (except mammography). Calgary Scientific, Inc. (Calgary, AB, USA) recently reported their latest Class II clearance from the US Food and Drug Administration (FDA). Calgary Scientific worked... Read more

Industry News

view channel

Collaboration Expands Capacity for Proton Therapy Clinical Research and Patient Treatments

Varian Medical Systems (Palo Alto, CA, USA) and the Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are extending an existing collaboration in the field of proton therapy to offer patients more accurate cancer treatments using intensity-modulated proton therapy (IMPT). Under the agreement, Varian will also... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.